BioSpace News Archive

Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that members of management will be participating in two upcoming investor conferences.

International Foundation for Gastrointestinal Disorders launches #IWant2Know, a social campaign for IBS Awareness Month.

ValGenesis Inc., a market leader in Enterprise Validation Lifecycle Management Solutions today announced the opening of two new offices in Mississauga, Canada and Long Beach, CA expanding its presence to accommodate rapid growth across North America .

LexisNexis ® Risk Solutions announced a collaboration with Clarify Health, a leading healthcare analytics company that provides AI-driven market intelligence and predictive analytics business applications to health systems, health plans, and life sciences companies.

PDC-1421, the active ingredient of ABV-1505, is being expanded into adult ADHD trials following encouraging Phase II trial results in major depressive disorder (MDD) First of six patients has been enrolled for Phase II Part I trial of ABV-1505 at the University of California, San Francisco (UCSF) Medical Center Phase II Part II trial of ABV-1505 is expected to follow Part I and be conducted at UCSF and major medical centers in Taiwan

In connection with the ongoing outbreak of Covid-19, caused by the new coronavirus, demand for disinfectants has snowballed and many products have suffered from supply shortages.

Relay Therapeutics, a new breed of company at the intersection of computation and biotechnology, announced today the appointment of top oncology experts, scientists and leaders to its newly formed oncology advisory board.

President of American Board of Clinical Lipidology and nationally recognized expert in cardiovascular disease prevention and the diagnosis and treatment of cholesterol and hypertensive disorders

IGM Biosciences, Inc. announced that members of the management team will present at two upcoming investor conferences

Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading company in leveraging computational biology to design novel products for life-science-based industries, announces today its financial results for the fourth quarter and full year, ending December 31, 2019.